NCT05611879 2023-12-29
Neoadjuvant of Tislelizumab Combined With Chemotherapy Followed by Surgery in Unresectable Stage â…¢ NSCLC
Beijing Tsinghua Chang Gung Hospital
Phase 2 Unknown
Clinical Trials
11 trialsNCT06154967 2023-12-04
To Explore the Effect of Immune-induced Stereotactic Body Radiotherapy (SBRT) on Reversing Immunoresistance in Stage IIIc/IV Non-small Cell Lung Cancer (NSCLC)
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase NA Unknown
NCT05228496 2023-09-26
A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLC
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT05798533 2023-07-10
Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03)
BGI, China
Phase 1 Unknown
NCT05900921 2023-06-13
Trilaciclib Prior to Chemotherapy Plus Tislelizumab as 1L Treatment for Advanced Squamous Non-Small-Cell Lung Cancer
Sichuan University
Phase 2 Unknown
NCT05527808 2023-06-08
A Single-arm Exploratory Study of Neoadjuvant Therapy
Guangzhou Institute of Respiratory Disease
Phase NA Unknown
NCT05192681 2022-01-14
Tislelizumab as Cross-line Treatment for Advanced NSCLC
Fujian Cancer Hospital
Phase 2 Unknown
NCT04405674 2021-11-22
Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLC
Shanghai Chest Hospital
Phase 2 Unknown
NCT05008861 2021-08-17
Gut Microbiota Reconstruction for NSCLC Immunotherapy
Shanghai Zhongshan Hospital
Phase 1 Unknown
NCT04865705 2021-04-29
Neoadjuvant Chemotherapy and Tilelizumab in Stage III（cTNM-IIIA.IIIB）Non-small-cell Lung Cancer
West China Hospital
Phase 2 Unknown
NCT04620837 2020-11-09
Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy
ChineseAMS
Phase 2 Unknown